^
Association details:
| Biomarker: | TNFRSF8 expression |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Drug: | Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
10/15/2019
Excerpt:
ADCETRIS is a CD30-directed antibody-drug conjugate indicated for treatment of adult patients with:...Previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
Secondary therapy:
doxorubicin hydrochloride + cyclophosphamide + prednisone
Source:
Title:
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
Excerpt:
...- Confirmed diagnosis of PTCL expressing CD30 receptor....
Trial ID:
Source:
Title:
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Excerpt:
...- Treatment-naive patients with CD30-expressing PTCL (Part F)...
Trial ID:
More C2 evidence
Source:
Title:
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Excerpt:
...Tumor specimen must be submitted before enrollment for subsequent central pathology review to confirm histology (and anaplastic lymphoma kinase (ALK) status, if applicable), and CD30 expression....
Trial ID:
Source:
Title:
A phase 2 study of retreatment with brentuximab vedotin in subjects with classic Hodgkin lymphoma or CD30-expressing peripheral T cell lymphoma Studio di fase 2 di ritrattamento con brentuximab vedotin in soggetti affetti da linfoma di Hodgkin classico o linfoma periferico a cellule T CD30-positivo
Excerpt:
...- Histologically confirmed cHL, sALCL, or other CD30-expressing PTCL.- Previously treated with brentuximab vedotin containing regimen, with evidence of objective response, and subsequent disease progression orrelapse after discontinuing treatment.- Documentation of disease relapse or progression > o = 6 months after the last dose of brentuximab vedotin.- Fluorodeoxyglucose positron emission tomography- (FDG-PET) avid and bidimensional measurable disease of at least 1.5 cm in longest axisas documented by radiographic technique.- An Eastern Cooperative Oncology Group (ECOG) performance status o = 6 mesi dopo l’ultima dose di brentuximab vedotin.- Malattia misurabile mediante tomografia ad emissione di positroni a base di fluorodesossiglucosio (FDG-PET) avidae bidimensionale di almeno 1,5 cm nell’asse più lungo come documentato dalla tecnica radiografica.- Stato di performance secondo l’Eastern Cooperative Oncology Group (ECOG) < o = 2- Non deve avere una gravidanza in corso e, se in età fertile o soggetto maschile in grado di concepire,deve accettare di utilizzare 2 metodi contraccettivi efficaci nel corso dello studio e per 6 mesi dopo l’ultima dose del farmaco dello studio.- Età o superiore a 18 anni.Potrebbero applicarsi criteri di inclusione aggiuntivi definiti dal protocollo....
Trial ID:
Source:
Title:
An open-label, phase 2 study of brentuximab vedotin and Chemotherapy agents in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) Étude en ouvert, de phase 2 à double cohorteportant sur le brentuximab védotine et les agents de chimiothérapie dans le traitement de première ligne de patients atteints de lymphome à cellules T périphérique (LCTP)
Excerpt:
...3.The following non-sALCL PTCL subtypes are eligible: a.PTCL – not otherwise specified (PTCL-NOS) b.Angioimmunoblastic T-cell lymphoma (AITL) c.Adult T-cell leukemia/lymphoma (ATLL; acute and lymphoma types only, must be positive for human T cell leukemia virus 1) d.Enteropathy-associated T-cell lymphoma (EATL) e.Hepatosplenic T-cell lymphoma f.Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITCL) g.Indolent T-cell lymphoproliferative disorder (T-LPD) of the gastrointestinal (GI) tract h.Follicular T-cell lymphoma i.Nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype 4.CD30 expression <10% by local assessment 5.Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT, as assessed by the site radiologist. ...
Trial ID:
Source:
Title:
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
Excerpt:
...Patients with either Hodgkin lymphoma or T-cell lymphoma must have expression of CD30 in ≥10% of lymphoma cells....
Trial ID:
Source:
Title:
Brentuximab Vedotin in Combination With CHEP in Patient With PTCL
Excerpt:
...Histologically confirmed diagnosis of CD30-expressing PTCL....
Trial ID:
Source:
Title:
Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas
Excerpt:
...Criteria of positive CD30 expression are defined as in cases with membranous CD30 expression from more than 50% of neoplastic cells....
Trial ID:
Source:
Title:
The standard of care for patients with newly diagnosed CD30-positive PTCL is treatment with a combination of drugs called CHOP. This study is conducted to improve the effectiveness of CHOP chemotherapy with combination therapy, in which vincristine is replaced by brentuximab vedotin. Also, the addition of etoposide to various chemotherapy regimens for T-lymphomas has been associated with promising results in several other studies. This combination is called A + CHEP. Standardem péče pro pacienty s nově zjištěným CD30 pozitivním PTCL je léčba kombinací léků zvaných CHOP. Tato studie se provádí s cílem zlepšit účinnost chemoterapie CHOP s kombinovanou léčbou, v níž se vinkristin nahradí přípravkem brentuximab vedotin. Taktéž přidání etoposidu do různých režimů chemoterapie u T-lymfomů bylo v několika dalších studiích spojeno se slibnými výsledky. Tato kombinace se nazývá A+CHEP [brentuximab vedotin plus cyklofosfamid, doxorubicin, etoposid, prednison].
Excerpt:
...Histologically confirmed diagnosis of CD30-expressing PTCL. ...
Trial ID:
Source:
Title:
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Excerpt:
...- CD30 expression ...
Trial ID:
Source:
Title:
CD30 Imaging in Diffuse Large B-cell Lymphoma
Excerpt:
...An optimized 89Zr-brentuximab imaging protocol for visualisation of CD30 distribution by PET-scan`Safety profile of the 89Zr-brentuximab tracer`Relation 89Zr-brentuximab biodistribution and CD30 expression...
Trial ID:
Source:
Title:
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Excerpt:
...- Histologically confirmed cHL, sALCL, or other CD30-expressing PTCL...
Trial ID:
Less C2 evidence
Source:
Title:
Efficacy and Safety of Retreatment with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or CD30-Expressing Peripheral T Cell Lymphoma
Published date:
11/03/2022
Excerpt:
...enrolled adult pts with r/r cHL and sALCL or other CD30-expressing PTCL...Pts were treated with BV...The ORR per investigator assessment was 83% (95% CI: 35.9, 99.6) with 4 pts achieving CR. The 4 pts with sALCL had an ORR of 100% with a CR rate of 75%....Preliminary results from this study show BV is a viable retreatment option for adults with r/r cHL, sALCL, and PTCL.
DOI:
https://doi.org/10.1182/blood-2022-158225
Trial ID:
Source:
Title:
ECHELON-2, (NCT01777152), 5-YEAR RESULTS OF A RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN + CHP VS CHOP IN PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA
Published date:
05/12/2021
Excerpt:
Adults with untreated CD30-positive PTCL (targeting 75% ± 5% with sALCL) were randomized 1:1 to receive 6–8 cycles of A+CHP or CHOP....Median time to retreatment for pts in the A+CHP arm was 15.0 months (range, 3–64); 17 pts (ORR: 59%) had CR (n=11) or partial remission (n=6) after retreatment with brentuximab vedotin monotherapy (n=25) or a brentuximab vedotin-containing regimen (n=4).
Secondary therapy:
doxorubicin hydrochloride + prednisone + cyclophosphamide intravenous
Trial ID:
Source:
Title:
Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas
Published date:
11/13/2019
Excerpt:
After 3 cycles of CHEP-BV the ORR was 100% with 58% CR (14 CR, 10 PR), and at completion of CHEP-BV the ORR was 95% with 90% CR (19 CR, 1 PR, 1 PD)....In pts with CD30-expressing PTCL, induction therapy with CHEP-BV is tolerable and associated with a high CR rate.
Secondary therapy:
doxorubicin hydrochloride + cyclophosphamide + etoposide oral + prednisone
DOI:
10.1182/blood-2019-123166
Source:
Title:
The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
Excerpt:
All patients were pathologically diagnosed to have PTCL before treatment and expressed CD30....the ORR reached 89.5% [CR 52.7%; partial response (PR) 36.8%]. In the ALCL group, CR reached 100% with the median duration of response of up to 8 months, while in the AITL group, the ORR was 75% and 2 patients had disease progression after treatment with BV + CEP....BV is a promising treatment in patients with ALCL, AITL and PTCL-TFH in frontline treatment settings.
Secondary therapy:
cyclophosphamide + epirubicin + prednisone
DOI:
10.1007/s12325-021-01943-z
